52 results on '"Papakostas, P"'
Search Results
2. 1858P Efficacy and safety of thromboprophylaxis in oncology patients with Khorana score
3. MA01.03 Thromboprophylaxis for Lung Cancer Patients: Combined Results from GMaT and ACT4CAT Studies
4. 2107P Thromboprophylaxis with intermediate or prophylactic doses of LMWHs in ambulatory cancer patients
5. A randomised phase III trial of adjuvant radio-chemotherapy comparing Irinotecan, 5FU and Leucovorin to 5FU and Leucovorin in patients with rectal cancer: A Hellenic Cooperative Oncology Group Study
6. Postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: safety analysis of the Hellenic Cooperative Oncology Group randomized phase III trial HE 10/00
7. Paclitaxel and gemcitabine vs. paclitaxel and pegylated liposomal doxorubicin in advanced non–nasopharyngeal head and neck cancer. An efficacy and cost analysis randomized study conducted by the Hellenic Cooperative Oncology Group
8. Evaluation of the prognostic and predictive value of p53 and Bcl-2 in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapy
9. Mutations of the epidermal growth factor receptor tyrosine kinase domain and associations with clinicopathological features in non-small cell lung cancer patients
10. Postoperative dose-dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high-risk operable breast cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group
11. Paclitaxel plus carboplatin versus paclitaxel plus alternating carboplatin and cisplatin for initial treatment of advanced ovarian cancer: long-term efficacy results: a Hellenic Cooperative Oncology Group (HeCOG) study
12. Irinotecan or oxaliplatin combined with leucovorin and 5-fluorouracil as first-line treatment in advanced colorectal cancer: a multicenter, randomized, phase II study
13. Paclitaxel and epirubicin versus paclitaxel and carboplatin as first-line chemotherapy in patients with advanced breast cancer: a phase III study conducted by the Hellenic Cooperative Oncology Group
14. 1585P Thromboprophylaxis “challenge” in oncology patients with high burden for thrombosis: Real-world data from GMaT and ACT4CAT studies
15. Neoadjuvant chemotherapy with a combination of pegylated liposomal doxorubicin (Caelyx®) and paclitaxel in locally advanced breast cancer: a phase II study by the Hellenic Cooperative Oncology Group
16. P159 - Should patients with active urological cancers receive thromboprophylaxis for Cancer Associated Thrombosis (CAT)?
17. Weekly paclitaxel as first-line chemotherapy and trastuzumab in patients with advanced breast cancer: A Hellenic Cooperative Oncology Group phase II study
18. First-line chemotherapy with docetaxel for unresectable or metastatic carcinoma of the biliary tract. A multicentre phase II study
19. Phase II study of temozolomide in heavily pretreated cancer patients with brain metastases
20. Ifosfamide plus oral etoposide salvage chemotherapy for platinum-resistant paclitaxel-pretreated ovarian cancer
21. Second-line chemotherapy with weekly oxaliplatin and high-dose 5-fluorouracil with folinic acid in metastatic colorectal carcinoma: A Hellenic Cooperative Oncology Group (HeCOG) phase II feasibility study
22. SO-2 Prevalence and prognostic role of inherited germline mutations in cancer predisposing genes in unselected patients with pancreatic cancer
23. 84P Actual 5-year survival of dose-dense sequential adjuvant chemotherapy in early breast cancer (BC) patients treated in the post-trastuzumab era: A pooled analysis of 3 clinical trials
24. 196P - The clinical impact of adjuvant dose-dense sequential chemotherapy (dds-CT) in patients with high-risk operable breast cancer (BC): Pooled analysis of 6 clinical trials
25. MON-PO476: Nutritional Status Assessment as a Surrogate to Clinical Outcome Prediction in Cardiac Surgery Patients
26. 1876P - Actionable mutations and overall survival in 3,211 patients with cancer: The Hellenic cooperative oncology group precision medicine initiative
27. 1848P - Predictive significance of tumour angiogenic and anti-angiogenic VEGF-A splice variants in patients with metastatic colorectal cancer
28. 1844P - Prognostic implications of mismatch repair deficiency in patients with early-stage colorectal and endometrial cancer
29. 1719P - Prevention and prophylaxis of thrombosis in cancer patients
30. 144P - Cyclin D1 differential activation and its prognostic impact among advanced breast cancer patients treated with trastuzumab
31. 183P - Intrinsic tumor features underlying clinical subtype discordance in early breast cancer
32. 523P - Mutational profiles in paired primary tumours and metastases in colorectal cancer patients: an NGS study of the Hellenic Cooperative Oncology Group
33. 104P - Evaluation of the association of HER family members with efficacy of trastuzumab therapy in metastatic breast cancer
34. 2336 Clinical and therapeutic aspects of neuroendocrine tumors: The Greek NET Registry
35. 1813 Interaction of TP53 mutations with trastuzumab in HER2-positive patients with operable breast cancer
36. PCN105 - Economic Evaluation of NAB-Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone for The Management of Metastatic Pancreatic Cancer in Greece
37. 1497P - Lessons from the Past: Long-Term Safety and Efficacy Outcomes of a Prematurely Terminated, Randomized Phase III Trial of Precautionary Versus Hemoglobin-Based Erythropoietin Administration for Chemotherapy-Associated Anemia in Patients with Solid Tumors
38. 258PD - Investigating the Clinical Relevance of Genomic Characteristics in Luminal a and B Breast Cancer (Bc)
39. 630 - Potential Biomarkers for Response to Cetuximab in Patients with Metastatic Colorectal Cancer (MCRC). A Hellenic Cooperative Oncology Group Study
40. 0187 Weekly docetaxel with or without gemcitabine as second line chemotherapy in paclitaxel pretreated patients with metastatic breast cancer: A randomised phase II study conducted by the Hellenic Co-operative oncology group
41. 541 POSTER Evaluation of the prognostic and predictive value of EGFR protein levels in primary tumors of high-risk breast cancer patients
42. 771 Paclitaxel and carboplatin as adjuvant treatment in high-risk patients with operable non-small cell lung cancer (NSCLC): A feasibility study conducted by the hellenic cooperative oncology group (HeCOG)
43. Use of amifostine (AMI) to reduce toxicity following Taxol-based chemotherapy in solid tumors. A randomized phase II study of the Hellenic Cooperative Oncology Group
44. Paclitaxel plus carboplatin versus paclitaxel plus gemcitabine in advanced NSCLC. Final results of a randomized phase III study
45. Docetaxel-vinorelbine combination for platinum resistant paclitaxel pretreated ovarian cancer. A hellenic co-operative oncology group phase II study
46. Taxotere—5FU Leucovorin (TFL) in advanced gastric carcinoma: a HeCOG phase II study
47. First line treatment with docetaxel (D) and gemcitabine (G) in patients with inoperable pancreatic cancer: a multicenter phase II study
48. Effectiveness of paclitaxel and carboplatin combination in heavily pretreated patients with head and neck cancers
49. 669 - Long term breast cancer treatment with tamoxifen and second primary tumors
50. 69 Intensified adjuvant chemotherapy for patients with breast cancer and > 10 positive lymph nodes. A phase II study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.